Tomáš Vaňásek

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt et al. · The Lancet · 2017 · 912 citations

Medicine, Internal Medicine, Gastroenterology +3

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese et al. · The Lancet · 2017 · 197 citations

Life Sciences, Immunology, Pharmacotherapy +14

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

Satish Keshav, Tomáš Vaňásek, Yaron Niv et al. · PLoS ONE · 2013 · 134 citations · Full text

Medicine, Immunology, Pharmacology +17

Risankizumab for Ulcerative Colitis

Edouard Louis, Stefan Schreiber, Remo Panaccione et al. · JAMA · 2024 · 110 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15